The 3rd Cardiovascular Outcome Trial Summit of the Diabetes & Cardiovascular Disease EASD Study Group was held on the 26-27 October 2017 in Munich. As in 2015 and 2016, this summit was organised in light of recently completed and published CVOTs on diabetes, aiming to serve as a reference meeting for in-depth discussions on the topic. Amongst others, the CVOTs EXSCEL, DEVOTE, the CANVAS program and the ACE-trial, which released primary outcome results in 2017, were discussed. Trial implications for diabetes management and recent perspectives of diabetologists, cardiologists, endocrinologists, nephrologists and general practitioners were highlighted. The clinical relevance of cardiovascular outcome trials and its implications regarding reimbursement were compared with real-world studies. The 4th Cardiovascular Outcome Trial Summit will be held in Munich 25-26 October 2018 ( http://www.dcvd.org ).

3rd Department of Internal Medicine Charles University 1st Faculty of Medicine U Nemocnice 1 Prague 2 128 08 Czech Republic

Clinic for Endocrinology Diabetes and Metabolic Diseases Clinical Center of Serbia Faculty of Medicine University of Belgrade Dr Subotica 13 Belgrade 11000 Serbia

Department of Cardiovascular and Metabolic Diseases IRCCS MultiMedica Via Milanese 300 20099 Sesto San Giovanni MI Italy

Department of Endocrinology Diabetology Nutrition Paris 13 University CINFO CRNH IdF Jean VERDIER Hospital Avenue du 14 Juillet 93140 Bondy France

Diabetes Endocrine and Metabolic Disease Unit IRCCS Centro Cardiologico Monzino Via Carlo Parea 4 20138 Milan Italy

Forschergruppe Diabetes e 5 Munich Ingolstaedter Landstrasse 1 Neuherberg 85764 Munich Germany

Institut d'Investigacions Biomèdiques August Pi i Sunyer Barcelona Spain

Internal Medicine Department Clinical County Emergency Hospital Constanta Tomis Blvd No 145 900591 Constanta Romania

Zobrazit více v PubMed

Dailey G. Overall mortality in diabetes mellitus: where do we stand today? Diabetes Technol Ther. 2011;13(Suppl 1):S65–S74. PubMed

Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589. doi: 10.1056/NEJMoa0806470. PubMed DOI

Bergenstal RM. Glycemic variability and diabetes complications: does it matter? Simply put, there are better glycemic markers! Diabetes Care. 2015;38(8):1615–1621. doi: 10.2337/dc15-0099. PubMed DOI

FDA . Guidance for industry diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Washington, D. C.: US Department of Health and Human Services; 2008.

Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf. Accessed 26 Feb 2015.

White WB, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–1335. doi: 10.1056/NEJMoa1305889. PubMed DOI

Scirica BM, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326. doi: 10.1056/NEJMoa1307684. PubMed DOI

Green JB, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242. doi: 10.1056/NEJMoa1501352. PubMed DOI

Pfeffer MA, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257. doi: 10.1056/NEJMoa1509225. PubMed DOI

Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844. doi: 10.1056/NEJMoa1607141. PubMed DOI

Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. doi: 10.1056/NEJMoa1603827. PubMed DOI PMC

Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. doi: 10.1056/NEJMoa1504720. PubMed DOI

Neal B, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. doi: 10.1056/NEJMoa1611925. PubMed DOI

Holman RR, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–1239. doi: 10.1056/NEJMoa1612917. PubMed DOI PMC

Marso SP, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377(8):723–732. doi: 10.1056/NEJMoa1615692. PubMed DOI PMC

Schnell O, et al. Updates on cardiovascular outcome trials in diabetes. Cardiovasc Diabetol. 2017;16(1):128. doi: 10.1186/s12933-017-0610-y. PubMed DOI PMC

Holman RR, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;S2213–8587(17):30309. PubMed

Sabatine MS, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713–1722. doi: 10.1056/NEJMoa1615664. PubMed DOI

H.T.R.C. Group Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377(13):1217–1227. doi: 10.1056/NEJMoa1706444. PubMed DOI

Schnell O, et al. Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2016;15:33. doi: 10.1186/s12933-016-0357-x. PubMed DOI PMC

Schnell O, et al. Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2017;16(1):35. doi: 10.1186/s12933-017-0508-8. PubMed DOI PMC

Chiasson JL, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359(9323):2072–2077. doi: 10.1016/S0140-6736(02)08905-5. PubMed DOI

Kosiborod M, et al. Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL Study. Circulation. 2017;136(3):249–259. doi: 10.1161/CIRCULATIONAHA.117.029190. PubMed DOI PMC

Johansson I, et al. Prognostic implications of type 2 diabetes mellitus in ischemic and nonischemic heart failure. J Am Coll Cardiol. 2016;68(13):1404–1416. doi: 10.1016/j.jacc.2016.06.061. PubMed DOI

Johansson I, et al. Risk factors, treatment and prognosis in men and women with heart failure with and without diabetes. Heart. 2015;101(14):1139–1148. doi: 10.1136/heartjnl-2014-307131. PubMed DOI

Johansson I, et al. Is the prognosis in patients with diabetes and heart failure a matter of unsatisfactory management? An observational study from the Swedish Heart Failure Registry. Eur J Heart Fail. 2014;16(4):409–418. doi: 10.1002/ejhf.44. PubMed DOI

Carls GS, et al. Understanding the gap between efficacy in randomized controlled trials and effectiveness in real-world use of GLP-1 RA and DPP-4 therapies in patients with type 2 diabetes. Diabetes Care. 2017;40(11):1469–1478. doi: 10.2337/dc16-2725. PubMed DOI

Standl E, et al. Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. Lancet Diabetes Endocrinol. 2017;5(5):391–402. doi: 10.1016/S2213-8587(17)30033-5. PubMed DOI

CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs

Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group